Incretin Atlas › Trials › DREAMS-2
DREAMS-2
Mazdutide · t2d
Design
- Molecule(s)
- Mazdutide
- Population
- t2d
- Official title
- A Study of IBI362 in Participants With Type 2 Diabetes
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- 3
- Registry status
- completed · 2023-01 → 2024-01
- Participants
- 731
- Duration
- 28 weeks
- Registry
- NCT05606913
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mazdutide 4 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 % | t2d china | 28 | — | — | −6.5 % | −1.6 | 2.1 | 8.7 | 35.5 | 24.0 | 5.8 | — | verified |
| mazdutide 6 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 % | t2d china | 28 | — | — | −8.5 % | −1.7 | 3.7 | 13.1 | 34.4 | 29.1 | 4.9 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- mazdutide 4 mg: Active-controlled vs dulaglutide 1.5 mg; primary end point HbA1c at week 28. Any-reason discontinuation computed from the trial profile (Fig. 1). Efficacy-estimand weight in a figure only.
- mazdutide 6 mg: Active-controlled vs dulaglutide 1.5 mg; primary end point HbA1c at week 28. Any-reason discontinuation computed from the trial profile (Fig. 1). Efficacy-estimand weight in a figure only.
Verbatim quotes from the source (14)
- mazdutide 4 mg · weight_tp · Results, Body weight paragraph 1; Table 2
with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
- mazdutide 4 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
TEAEs that led to study treatment discontinuation occurred in five (2.1%) participants who received 4 mg mazdutide
- mazdutide 4 mg · disc_any · Fig. 1 (trial profile)
N6[242 received at least one dose] --> N9[21 discontinued study treatment: Adverse event: 5 br Withdrawal by participant: 16]
- mazdutide 4 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
nausea (35.5%, 34.4% and 17.1%)
- mazdutide 4 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
vomiting (24.0%, 29.1% and 14.3%)
- mazdutide 4 mg · sae · Results, Safety paragraph 1; Table 3
adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
- mazdutide 4 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)
- mazdutide 6 mg · weight_tp · Results, Body weight paragraph 1; Table 2
with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
- mazdutide 6 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
nine (3.7%) who received 6 mg mazdutide and four (1.6%) who received 1.5 mg dulaglutide (Table 3 and Extended Data Table 2)
- mazdutide 6 mg · disc_any · Fig. 1 (trial profile)
N7[244 received at least one dose] --> N12[32 discontinued study treatment: Adverse event: 9 br Withdrawal by participant: 22 br Physician decision: 1]
- mazdutide 6 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
nausea (35.5%, 34.4% and 17.1%)
- mazdutide 6 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
vomiting (24.0%, 29.1% and 14.3%)
- mazdutide 6 mg · sae · Results, Safety paragraph 1; Table 3
adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
- mazdutide 6 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)
Primary sources
- Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652(8108):181-188. PMID: 41407860.
- ClinicalTrials.gov NCT05606913
How to cite this page
Medical Adviser's Group. Incretin Atlas: DREAMS-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.